Beyond the Guidelines: Perspectives on the Role of PARP
Inhibition in the Management of Ovarian Cancer — Interview with Dr
Coleman on the following topics:
Clinical implications of the Phase III VELIA study assessing
veliparib in combination with carboplatin/paclitaxel and as
continuation maintenance therapy for newly diagnosed advanced
OC (00:00)
Homologous recombination deficiency testing and implications
for treatment decision-making in newly diagnosed advanced OC
(4:11)
Risks with combining PARP inhibitor therapy and chemotherapy
for advanced OC; optimizing the use of chemotherapy, bevacizumab
and a PARP inhibitor in the front-line setting (7:19)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.